Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 16, 2009

Lonza to Manufacture Elusys’ Antianthrax mAb

  • Lonza signed an agreement with Elusys Therapeutics for the manufacture of Anthin™, Elusys’ late -stage mAb against inhaled anthrax. Under terms of the deal, Lonza will provide process development services and manufacture the product using its GS Gene Expression System™.

    Anthin is a humanized, deimmunized mAb that targets the protective antigen of B. anthracis and neutralizes the effects of anthrax toxins. The antibody is being developed for both the prevention and treatment of inhalation anthrax. Elusys has been awarded $34 million from the NIH and DOD for development of the antibody. The product has also been granted fast-track status and orphan drug designation by the FDA. 



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »